Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Brian M. Culley, the company's CEO, will be presenting at the event. The presentation will be available for on-demand viewing starting at 7:00am ET on the day of the conference for registered attendees.
Interested parties can also access a replay of the presentation on the Events and Presentations section of Lineage's website. The company specializes in developing allogeneic cell therapies for unmet medical needs, particularly in the field of ophthalmology. Additional videos showcasing Lineage's work are available on the Media page of their website.
Lineage Cell Therapeutics, Inc. (NYSE American e TASE: LCTX), una compagnia biotecnologica in fase clinica, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright che si terrà il 15 agosto 2024. Brian M. Culley, CEO dell'azienda, presenterà all'evento. La presentazione sarà disponibile per la visione on-demand a partire dalle 7:00 ET nel giorno della conferenza per i partecipanti registrati.
Le parti interessate potranno anche accedere a un replay della presentazione nella sezione Eventi e Presentazioni del sito web di Lineage. L'azienda si specializza nello sviluppo di terapie cellulari allogeniche per esigenze mediche non soddisfatte, in particolare nel campo dell'oftalmologia. Ulteriori video che mostrano il lavoro di Lineage sono disponibili nella pagina Media del loro sito web.
Lineage Cell Therapeutics, Inc. (NYSE American y TASE: LCTX), una empresa biotecnológica en etapa clínica, ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright que se llevará a cabo el 15 de agosto de 2024. Brian M. Culley, el CEO de la compañía, estará presentando en el evento. La presentación estará disponible para su visualización bajo demanda a partir de las 7:00 a.m. ET en el día de la conferencia para los asistentes registrados.
Las partes interesadas también podrán acceder a una repetición de la presentación en la sección de Eventos y Presentaciones del sitio web de Lineage. La empresa se especializa en el desarrollo de terapias celulares alogénicas para necesidades médicas no satisfechas, en particular en el campo de la oftalmología. Videos adicionales que muestran el trabajo de Lineage están disponibles en la página de Medios de su sitio web.
Lineage Cell Therapeutics, Inc. (NYSE American 및 TASE: LCTX)는 임상 단계의 생명공학 회사로, 2024년 8월 15일에 열리는 H.C. Wainwright 제4회 연례 안과 가상 회의에 참여한다고 발표했습니다. Brian M. Culley CEO가 이 행사에서 발표할 예정입니다. 발표는 회의 당일 등록된 참석자를 위해 동부 표준시 기준 오전 7:00부터 주문형 시청이 가능합니다.
관심 있는 분들은 Lineage 웹사이트의 이벤트 및 발표 섹션에서 발표의 재생을 확인할 수 있습니다. 이 회사는 시급한 의료 요구를 위해, 특히 안과 분야에서 알로겐 세포 치료제를 개발하는 데 특화되어 있습니다. Lineage의 작업을 보여주는 추가 비디오는 웹사이트의 미디어 페이지에서 확인할 수 있습니다.
Lineage Cell Therapeutics, Inc. (NYSE American et TASE: LCTX), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie de H.C. Wainwright qui aura lieu le 15 août 2024. Brian M. Culley, le PDG de l'entreprise, présentera lors de cet événement. La présentation sera disponible en replay à partir de 7h00 ET le jour de la conférence pour les participants inscrits.
Les parties intéressées peuvent également accéder à une rediffusion de la présentation dans la section Événements et Présentations du site Web de Lineage. L'entreprise se spécialise dans le développement de thérapies cellulaires allogéniques pour des besoins médicaux non satisfaits, en particulier dans le domaine de l'ophtalmologie. D'autres vidéos présentant le travail de Lineage sont disponibles sur la page des Médias de leur site Web.
Lineage Cell Therapeutics, Inc. (NYSE American und TASE: LCTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright am 15. August 2024 angekündigt. Brian M. Culley, der CEO des Unternehmens, wird bei der Veranstaltung präsentieren. Die Präsentation wird am Tag der Konferenz ab 7:00 Uhr ET für registrierte Teilnehmer im On-Demand-Format verfügbar sein.
Interessierte können auch eine Wiederholung der Präsentation im Abschnitt Veranstaltungen und Präsentationen auf der Website von Lineage abrufen. Das Unternehmen spezialisiert sich auf die Entwicklung von allogenen Zelltherapien für ungedeckte medizinische Bedürfnisse, insbesondere im Bereich der Augenheilkunde. Weitere Videos, die die Arbeit von Lineage zeigen, sind auf der Medienseite ihrer Website verfügbar.
- None.
- None.
Interested parties can also register to view a replay of the presentation on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813574683/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212) 845-4242
Source: Lineage Cell Therapeutics, Inc.
FAQ
When is Lineage Cell Therapeutics (LCTX) presenting at the H.C. Wainwright Ophthalmology Conference?
Who will be presenting for Lineage Cell Therapeutics (LCTX) at the conference?
How can investors access Lineage Cell Therapeutics' (LCTX) presentation from the conference?
What type of therapies does Lineage Cell Therapeutics (LCTX) develop?
